Company intelligence / Profile preview

RenaBio

Long Island City, New York, United Statessustainablecarbon.com ↗

Ownership: Private
Development stage: Other

Overview

RenBio develops next-generation DNA therapeutics enabling patients to produce their own therapeutic antibodies or proteins using its proprietary MYO Technology. Its lead asset, RB‑100—a bispecific antibody targeting SARS-CoV‑2—has demonstrated strong preclinical efficacy against multiple variants. The company’s broader pipeline targets infectious, inflammatory, hematologic, and metabolic diseases. No clinical results have been published yet.

Therapeutic areas: HematologyImmunologyMetabolic DisordersInfectious Diseases
Modalities: DNA therapyBispecific antibodyAntibody
Industry: Biotech

Partnerships

Defense Advanced Research Projects Agency (DARPA)Bill & Melinda Gates FoundationBiomedical Advanced Research and Development Authority (BARDA)Wellcome Trust

Beyond the preview

Go deeper on RenaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenaBio.

Explore the full profile